WPC
PDSB icon

White Pine Capital’s PDS Biotechnology PDSB Stock Holding History

White Pine Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-581
Closed -$109K – 247
2017
Q4 		$109K Hold
581
– – 0.04% 211
2017
Q3 		$125 Buy
+581
New +$120K ﹤0.01% 210
2016
Q2 		– Sell
-581
Closed -$106K – 217
2016
Q1 		$106K Buy
+581
New +$104K 0.05% 201

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

White Pine Capital's PDSB Position: Q1 2018 in Review

White Pine Capital sold out of PDS Biotechnology (PDSB) in Q1 2018, closing a stake of 581 shares — an estimated $109K sold.

White Pine Capital first reported a position in PDSB in Q1 2016 and held it in 3 quarters. The position peaked at $109K in Q4 2017. 60 funds tracked by Wall St. Rank hold PDSB as of Q1 2018.

  • White Pine Capital reported no remaining PDS Biotechnology position as of Q1 2018 after selling out during the quarter.
  • White Pine Capital sold 581 PDS Biotechnology shares in Q1 2018, an estimated $109K.
  • White Pine Capital first reported a position in PDS Biotechnology in Q1 2016 and held it in 3 quarters.
  • White Pine Capital's PDS Biotechnology position peaked at $109K in Q4 2017.
  • 60 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2018.

Based on White Pine Capital's 13F filing for Q1 2018, filed 14 May 2018.